Positive top-line results from the pivotal BLUE-C study showed that the next-generation Cologuard met all study endpoints and improved every top-line metric, including a 30% lower false positive rate compared to DeeP-C, the FDA registrational trial for Cologuard.
New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine suggests that one’s biological age, which can be higher than his or her chronological age – a concept called accelerated aging – may predict who’s at risk for developing colon polyps, a known risk factor for colorectal cancer.
